Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.58 |
| ▸ | CDK4 | P11802 | 12/20 | 0.53 |
| ▸ | AURKA | O14965 | 6/20 | 0.53 |
| ▸ | CDK1 | P06493 | 6/20 | 0.53 |
| ▸ | CDK7 | P50613 | 6/20 | 0.53 |
| ▸ | CDK9 | P50750 | 6/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.53 |
| ▸ | PLK1 | P53350 | 3/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801535 | 0.87 | CDK2 (0.76) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL5620875 | 0.87 | CDK2 (0.76) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL5620822 | 0.85 | CDK2 (0.69) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL4804455 | 0.85 | CDK2 (0.76) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL14562033 | 0.84 | CDK2 (0.62) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL5621800 | 0.84 | CDK2 (0.70) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL4797417 | 0.83 | CDK2 (0.60) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL4802297 | 0.83 | CDK2 (0.57) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL4802162 | 0.82 | CDK2 (0.76) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL4800417 | 0.82 | CDK2 (0.59) | CDK2CDK4AURKACDK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241297-A1 | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1648887-A1 | PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012298-A1 | PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241297-A1 | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | FRK, CNKSR1, TYK2 | CDK2 8/4885CDK4 76/4885AURKA 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.